bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.06.14.732129

Metrics for Evaluating Biological AI Model Predictive Accuracy at the Data-Substrate Level

Abstract

SummaryReports in the biological literature disagree on whether a given model can predict a biological outcome from a given data sample -- one study finding a model capable, another, on the same kind of data, finding it is not. This is particularly a challenge in relation to LLMs-where the models are large and opaque, with weights and training data inaccessible. Such disagreements cannot be settled by directly inspecting the model. To address this challenge, we consider an alternative approach: assessing whether the data sample is adequate to support the prediction asserted. For a given dataset, its substrate -- the underlying structure of the data -- determines what any model can recover, independent of architecture or capacity. At the same time, predicting the present state of a biological process and predicting the direction of its future change are different tasks; the second is supportable among AI models only where the data encode direction as determinable from the state -- a property we call encoding -- and is unsupportable where the same observed state precedes change in opposite directions -- a property we call non-identifiability, in the informational rather than the statistical sense. We introduce two generic metrics, Predictive Blindness Risk (PBR) and Prediction Indeterminacy Measure (PIM), that evaluate a data substrate for predictive accuracy directly -- without access to model weights, architecture, or training data -- and locate the regions of a data substrate where a predictive claim can be supported and where it cannot. Using human biological subjects, we employ the Yale Brain Metastases Longitudinal Data (1,430 human subjects; 11,892 MRI studies; four sequences) and show that direction of change was non-identifiable across regions encompassing the majority of transitions; a nonlinear AI model gained essentially nothing over majority-direction prediction there while recovering direction near-perfectly where the state encoded it; and model accuracy tracked data-substrate resolvability continuously (Spearman {rho} = -0.95 to -1.00). The metrics adjudicate, before any model is trusted and from the data alone, where claims of predictive accuracy -- of state, or of the law of change -- can be supported. BackgroundModel prediction of a biological outcome from a given data sample is often highly contested -- particularly in predicting biological change. The literature reports conflicting capability for the same kind of data and when complex models or opaque LLMs are used, the disagreement cannot be resolved by inspecting the model or its benchmark training data. Such disagreement has two sources -- instability of the model, and indeterminacy of the data -- of which only the first has been studied. We address the second by relocating the question from the model to the data substrate. MethodsWe analysed human biological data taken from the Yale Brain Metastases Longitudinal Data (1,430 human subjects; 11,892 MRI studies; four sequences) using transitions between consecutive scans. An observed-measure proxy grouped subjects into matched observed states. We defined two data-substrate metrics -- Predictive Blindness Risk (PBR), the minority-direction fraction at a matched state, and Prediction Indeterminacy Measure (PIM), the separation between admissible trajectories at a state -- and evaluated state-only prediction with subject-level-split logistic regression and a multilayer perceptron against a majority-direction baseline. At bin level across all eight bins per sequence, we computed the Spearman correlation between PBR and held-out model accuracy. Formal results established when a single-valued predictor cannot recover direction at a shared state (Appendix); a controlled simulation with a known governing law served as comparison. ResultsAcross sequences, 6-7 of 8 matched-state bins contained transitions in both directions, encompassing 75-88% of transitions; weighted PBR ranged 0.30-0.35 (mean 0.33, SD 0.01). In these non-identifiable bins the nonlinear model did not exceed majority-direction prediction (model-majority -0.014 to +0.001 across sequences and splits); in the complementary encoding bins (12-25% of transitions) accuracy reached 0.958-1.000. Across all bins, model directional accuracy declined monotonically with PBR (Spearman{rho} = -0.952 FLAIR, -0.976 T1 post-contrast, -1.000 T1 pre-contrast, -0.976 T2; P [≤] 3.3x10-5 in three sequences, 2.6x10-4 in FLAIR), establishing a continuous gradient of data-substrate resolvability rather than a binary partition. PBR was stable across binning resolution (range 0.299-0.353; CV 5.4%). In the simulation the state-only model predicted the wrong direction for every minority-direction subject while retaining significant overall association ({rho} = 0.46); theoretical PBR tracked empirical failure ({rho} = 0.96). ConclusionsState-only prediction recovers directional structure where the data substrate encodes it and cannot where the substrate is non-identifiable, with model accuracy varying continuously between the two as a near-deterministic function of data-substrate resolvability. The contested question of model predictive capability is therefore, in part, a prior question about the data: PBR and PIM answer it from the data alone, without access to model weights, architecture, or training data, and discriminate the regions of a data substrate where a claim of predictive accuracy -- of state, or of the law of change -- is and is not supportable.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ewing, M. A.. 2026-06-18. Metrics for Evaluating Biological AI Model Predictive Accuracy at the Data-Substrate Level. https://doi.org/10.64898/2026.06.14.732129

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗